Effects of acupoint injection for stroke patients with hemiplegia
A protocol for systematic review and meta-analysis of randomized controlled trials

Minghui Liu, MDa,b,∗, Yinyu Wang, MD, Ning Li, PhD, Jin Cui, PhD, WenRui Fan, BD, Shuo Yang, MD, Li Li, BD, Jie Zeng, MD, Min Li, PhD

Abstract
Background: Acupoint injection has currently received increasing attention as a treatment for hemiplegia. A number of studies have reported that acupoint injection have some advantages in treatment of hemiplegia. However, currently no article has summarized the existing evidence. Our study will evaluate the efficacy and safety of acupoint injection as a clinical treatment for hemiplegia, so that it can provide an important reference for clinical decision-making.

Methods: Randomized controlled trials and case control studies of acupoint injection for hemiplegia according to the included and excluded standard were identified in searches of 6 databases from their inception to February 2021. All data were assessed and extracted by 2 authors independently. The risk of bias assessment recommended by the Cochrane Collaboration was used to assess the quality of the selected studies. Review Manager 5.4 (Cochrane Collaboration) was used to conduct meta-analysis for the efficacy and safety of acupoint injection.

Result: The results of this systemic review and meta-analysis will be submitted to a recognized journal for publication.

Conclusion: This systemic review and meta-analysis will evaluate the efficacy and safety of acupoint injection as a clinical treatment for hemiplegia. We hope this study can make a definitive conclusion for acupoint injection in the treatment of hemiplegia.

Registration: PROSPERO (registration number CRD42021234453).

Abbreviation: RCTs = randomized controlled trials.

Keywords: acupoint injection, hemiplegia, meta-analysis, protocol, systematic review

1. Introduction
The global population will contain an estimated 70 million stroke survivors in 2030.[1] A total of 75% of stroke survivors exhibit varying degrees of dysfunction, commonly involving functional impairment of the lower extremities.[2] Neuro-rehabilitation has become a key part of post-stroke treatment, an important component of which is the restoration of lower extremity function.[3,4] However, evidence demonstrating which rehabilitation types best promote mobility in post-stroke patients is scarce.

According to the current practice guidelines, the patients with limb paralysis should get out of bed as soon as possible after their condition is stable, carry out standing and walking rehabilitation training with the aid of instruments, pay attention to muscle strength training of paralyzed limbs, and carry out progressive resistance training for corresponding muscles. Isokinetic muscle strength training can improve the function of paralyzed limbs after stroke, and carry out functional electrical stimulation therapy and electromyographic biofeedback therapy for corresponding muscles at the same time, combined with conventional rehabilitation treatment is also recommended. Acupoint injection is one of the methods of acupuncture.[5,6] In China, it was wildly used to treat stroke patients with hemiplegia to obtain a better curative effect and reduce bad reaction.

Acupoint injection is a supplementary replacement therapy, also known as “water needle,” that involves treating diseases by injecting appropriate medication into relevant acupoints, such as Mingmen (DU 34), Tsusanli (ST 36), and Sanyinjiao (SP6). The theory of traditional Chinese medicine holds that acupoint injection reinforces liver and kidney function and strengthens...
2. Methods

2.1. Study registration and ethics

This protocol has been registered at PROSPERO (registration number: CRD42021234453; http://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021234453). Data from individual patients will not be used in this systematic review and no privacy will be involved. So the ethical approval is not necessary.

2.2. Selection criteria

2.2.1. Type of study. We will include randomized controlled trials (RCTs) and case control studies of acupoint injection for hemiplegia; the language of the literature will not be limited. Controlled clinical trials, case reports, review articles, conference abstracts, editorials, letters, and expert opinions will be excluded.

2.2.2. Participants. Studies enroll patients diagnosed as stroke by computed tomography or magnetic resonance imaging and inclusion of patients with unilateral hemiplegia. Characteristics such as age, sex, and ethnicity were not restricted.

2.2.3. Interventions. The experiment group should be applied alone with acupoint injection combined with other basic treatment (electroacupuncture, message, rehabilitation training, etc) the drug types for acupoint injection, the acupuncture points for injection, treatment frequency, and duration of treatment will not be restricted. The control group was treated with basic treatment the same as intervention group.

2.2.4. Outcomes. The primary outcomes is the motor function, the secondary outcomes are score of Fugl-Meyer assessment and the stage of muscle strength, for example, knee joint muscle strength, hip joint muscle strength. The additional outcomes are self care ability of daily life and neurological function.

2.2.5. Search strategy. We will search 6 databases including PubMed, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure (CHKD-CNKI), Chinese Biomedical Literature Database (CBM), and WanFang Database (Chinese Medicine Premier). We will search all the databases from their inception to February 2021 by 2 independent authors. The search terms “point injection,” “acupoint injection,” and “hemiplegia,” “cerebrovascular disorders,” “stroke,” “paresis.” The medical subject heading terms “hemiplegia,” “acupuncture,” “acupuncture points,” or “injection” will be used.

2.2.6. Data extraction. Data will be extracted by 2 authors independently. All differences will be settled by discussion between the 2 researchers. If we cannot reach an agreement, we will consult a third reviewer. Data extract including the basic information of the trial (name of the first author, year of publication, the country study carried out), basic research information (patient information, experimental intervention, control intervention), evaluation time, outcomes (ADL score, Fugl-Meyer assessment, Ashworth score, etc), and relevant important variables. If information is missing, we contact the authors of the primary studies.

2.2.7. Quality assessment. Assessment of the risk of bias of the included studies will be performed independently by 2 authors and will be ranked as high, low, or uncertain. RCTs will use the Cochrane Collaboration’s risk of bias tool, this tool assesses the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. We will rate each domain as low, unclear, or high risk of bias. Case control studies will use Newcastle–Ottawa scale. Using that scale, 9 = maximum score, ≥6 is relatively high quality, 5 to 6 is fair quality, <5 is poor quality.

2.2.8. Statistical analysis

2.2.8.1. Meta-analysis. We will perform meta-analysis using Review Manager Software 5.4 (Cochrane Collaboration, London, United Kingdom). Dichotomous variables will be calculated as relative risk with 95% confidence interval (CI), and continuous variables will be calculated as the mean difference or standardized mean difference with 95% CI.

2.2.8.2. Measures for heterogeneity. The degree of heterogeneity ($I^2$) of each outcome will be analyzed using the Chi-squared test, with no significance designate by $P > .05$. $I^2 < 50\%$ indicates low heterogeneity of the data and the fixed model adopted for a meta-analysis; otherwise the random effects model will be used. If substantial heterogeneity is detected, subgroup or sensitivity analysis is applied to explore the causes of heterogeneity. If the sources of heterogeneity could not be determined, we adopt descriptive analysis.

2.2.8.3. Publication bias. Funnel plot and Egger test will be applied to evaluate the existence of publication bias.

3. Discussion

A number of RCTs and case-control studies have shown the efficacy and safety of acupoint injection for the treatment of hemiplegia. While the participants included in the studies were relatively small, in the same time no article has summarized the evidence now existed.

Due to the small simple, we cannot judge the efficacy and safety of acupoint injection accurately. Therefore, we conduct this systemic review and meta-analysis so as to provide reliable evidence for clinical promotion of acupoint injection for stroke patients with hemiplegia. If acupoint injection for hemiplegia is really efficacy and safety, this systemic review could give patients and clinicians several recommendations.

This protocol has been registered, we will strictly execute according to the Cochrane Handbook for Systematic Reviews of Interventions and is presented as per the preferred reporting items for systematic reviews and meta-analyses (PRISMA).
However, there may be several limitations in this study. Firstly, we include only English and Chinese literatures that will be lead to selection bias. Secondly, for most primary studies, the points chose for injection, the treatment frequency and duration of treatment are different, which may cause heterogeneity. Third, the severity of hemiplegia may also affect the results of this study. If the heterogeneity is high, we will conduct a subgroup analysis. Fourthly, our research is based on present research, the emergence of new research in the future may have an impact on current results. So we will update the systematic reviews. In conclusion, we hope this study can make a definitive conclusion for acupoint injection in the treatment of hemiplegia.

Author contributions
Conceptualization: Minghui Liu, Ning Li, Min Li.
Data curation: Shuo Yang, Li Li, Wenrui Fan.
Funding acquisition: Minghui Liu, WenRui Fan.
Methodology: Jin Cui, Shuo Yang, Li Li.
Project administration: Yinyu Wang, WenRui Fan.
Protocol draft: Minghui Liu, Ning Li.
Resources: Minghui Liu, Min Li.
Study Design: Minghui Liu, Min Li, and Ning Li.
Software: Jie Zeng.
Validation: WenRui Fan, Min Li.
Writing – original draft: Minghui Liu, Ning Li, Shuo Yang.
Writing – review & editing: Min Li.

References
[1] Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245–56.
[2] Sun J, Guo Y, Wang X, et al. mHealth for aging China: opportunities and challenges. Aging Dis 2016;7:53–67.
[3] Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011;377:1693–702.
[4] Pollock A, Farmer SE, Brady MC, et al. Interventions to improve arm and hand function in people after stroke. The Cochrane Library 2014.
[5] Kleinendorf DO, Towghigh A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52:e364–467.
[6] Zhang T, Zhao J, Bai YL, et al. Chinese guidelines for clinical management of cerebrovascular diseases (excerpted Edition) – stroke rehabilitation management. Chin J Stroke 2019;14:823–31.
[7] Huang R, Li XX, Xu SH, et al. Acupoint injection treatment for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 2019;8:586–95.
[8] Krause MS, Nakajima ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gynecol Clin North Am 2015;42:163–79.
[9] Tian J, Zhang J, Ge L, et al. The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol 2017;85:30–8.
[10] Yao L, Sun R, Chen YL, et al. The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 2016;74:73–9.
[11] Xiu-xia L, Zheng Y, Chen YL, et al. The reporting characteristics and methodological quality of Cochrane reviews about health policy research. Health Policy 2015;119:503–10.
[12] Chen HX, Yang ZJ, Pan RH, et al. Effect of comprehensive protocol of integrative medicine on motor function active of daily living and quality of life in hemiplegia patients after stroke. Zhongguo Zhong Xi Yi Jie He Za Zhi 2016;36:395–8.
[13] Lin AX, Zhu RM. The effect of Edaravone combined with fibrinolytic enzyme in the treatment of acute cerebral infarction. Anhui Med J 2015;36:469–71.
[14] Xiang Y, Wang H, Ni JJ, et al. Effects of different frequency electroacupuncture on upperlimb spasticity in patients with stroke based on EMG and MMG signal evaluation. Chin J Integr Med Cardio/ Cerebrovasc Dis 2017;15:541–6.
[15] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928–8.
[16] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 2009;339:b2700–0.
[17] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:557–62.
[18] Loannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations. PLoS One 2007;2:e41–1.
[19] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.